DBL Pharma wins 2nd position in methocarbamol market of USA

DBL Pharma Inc, DBL Group's registered new initiative in USA, won the 2nd position with a share of 14.20 per cent among 13 companies, according to a recently released report by IQVA (previously known as IMS); in the methocarbamol generic tablet market of USA, said a statement.
Indian company Granules Pharma's partner company in USA won the first position.
Methocarbamol is a widely used medicine in USA for muscle pain. After the expiration of the patent propriety of the first marketer of this medicine; mostly the Indian generic medicine companies started occupying the market share. By the end of 2018, DBL group and Beximco Pharma of Bangladesh got approval of US FDA to market this medicine in USA.
DBL Group is investing in Pharmaceutical industry hand in hand with their success in export based RMG and ceramics business. With an investment of Tk 7.00 billion and with the standard of US FDA; DBL Pharmaceuticals' factory in Kashimpur, Gazipur will start producing medicines for Bangladesh market by the end of this year.
In this factory consisting almost 10 acres of land; European machineries are being set up for making Tablets, Capsules, Syrup, Injection, Inhaler along with all other types of medicines.
Along with that, DBL also purchased production and quality control technology and machineries of Cream and Ointment of recently announced closed factory GlaxoSmithKline (GSK) Bangladesh Ltd.'s factory in Chattogram. As a result, DBL Pharma would be able to produce and serve the patients with the substitutes of Betnovate, Bactroban and other relevant medicines with the same quality control mechanisms using the same facility and technology that was being used by GSK.